Gadqua 列车市场规模、份额及成长分析（按应用程式、最终用户和地区）- 2025 年至 2032 年产业预测

2023 年，电子设备季铵盐-2 市场规模价值 19 亿美元，预计将从 2024 年的 20 亿美元成长到 2032 年的 29.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.1%。

预计 MRI显影剂市场将出现显着增长，这得益于癌症、神经系统疾病和心血管疾病等慢性疾病的发病率不断上升，这些疾病需要精确的成像才能进行有效的诊断和治疗计划。最新的进展包括四聚体钆四极体，这是一种高效的分子钆基显影剂(mGBCA)，以其优异的物理化学特性而闻名，例如高弛豫率和稳定性以及最小的蛋白质结合。该药物反映了现有 mGBCA 的药物动力学特征，表现出快速分布和肾臟排泄。此外，老年人口的成长和对非侵入性诊断技术的日益倾向预计将在未来几年进一步推动市场成长，凸显 MRI显影剂在现代医疗保健中的重要作用。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究

加德库阿火车市场规模（按应用）及复合年增长率（2025 年至 2032 年）

• 市场概览
• 筛检
• 诊断

加德库阿火车市场规模（依最终用户划分）及复合年增长率（2025-2032 年）

• 市场概览
• 医院
• 诊断中心
• 专科诊所
• 其他的

加德库阿火车市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Bayer AG（Germany）
• GE Healthcare（United States）
• Guerbet Group（France）
• Bracco Imaging SpA（Italy）
• Lantheus Medical Imaging, Inc.（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Spago Nanomedical AB（Sweden）
• Trivitron Healthcare（India）
• Jodas Expoim Pvt. Ltd.（India）
• CMR Naviscan Corporation（United States）
• Subhra Pharma Pvt. Ltd.（India）
• Macrocyclics, Inc.（United States）
• iMax Diagnostic Imaging Limited（China）
• Beijing Beilu Pharmaceutical Co., Ltd.（China）
• Jiangsu Hengrui Medicine Co., Ltd.（China）
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.（China）
• Yantai Dongcheng Pharmaceutical Group Co., Ltd.（China）
• Sanochemia Pharmazeutika AG（Austria）
• Medtronic plc（Ireland）

结论和建议

Gadoquatrane Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2.0 billion in 2024 to USD 2.97 billion by 2032, growing at a CAGR of 5.1% during the forecast period (2025-2032).

The MRI contrast media agents market is poised for substantial growth, fueled by the rising incidence of chronic diseases including cancer, neurological disorders, and cardiovascular issues that necessitate precise imaging for effective diagnosis and treatment planning. Among the latest advancements is tetrameric gadoquatrane, a highly effective molecular gadolinium-based contrast agent (mGBCA) known for its superior physicochemical properties, such as high relaxivity and stability, along with minimal protein binding. This agent mirrors the pharmacokinetic profiles of existing mGBCAs, demonstrating rapid distribution and kidney excretion. In addition, the expanding elderly population and the increasing inclination towards non-invasive diagnostic techniques are anticipated to further catalyze market growth over the coming years, underscoring the critical role of MRI contrast agents in contemporary healthcare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Gadoquatrane market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Gadoquatrane Market Segments Analysis

Global Gadoquatrane Market is segmented by Application, End User and region. Based on Application, the market is segmented into Screening and Diagnosis. Based on End User, the market is segmented into Hospital, Diagnostic Centres, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Gadoquatrane Market

The Gadoquatrane market is being driven by the escalating demand for MRI contrast media agents, fueled by several key factors. Notably, the rising prevalence of chronic illnesses, an aging population, and the preference for non-invasive diagnostic methods are significantly contributing to this trend. Additionally, advancements in technology and increased healthcare expenditures are further enhancing market growth. Research has shown the effectiveness of gadolinium-based contrast agents (GBCAs) in contrast-enhanced magnetic resonance imaging (CE-MRI), with over 620 million treatments administered globally and around 30 million CE-MRI procedures conducted annually. GBCAs, particularly those featuring paramagnetic gadolinium, optimize MRI signal enhancement, making Gadoquatrane an exceptional candidate for clinical development and increasing its demand in the market.

Restraints in the Gadoquatrane Market

Several factors contribute to the constraints on demand and subsequent price reduction for MRI contrast media agents in the Gadoquatrane market. Notably, the high costs associated with these agents lead both patients and healthcare providers to consider alternative diagnostic methods, especially in light of the increasing healthcare expenditure. Additionally, advancements in non-contrast MRI techniques are enhancing their accuracy and efficacy, thereby diminishing the reliance on contrast agents. Safety concerns, including rare adverse effects such as allergic reactions and nephrogenic systemic fibrosis (NSF), further discourage use. Furthermore, the healthcare industry's shift towards value-based care promotes high-quality yet cost-effective solutions, encouraging a preference for other imaging modalities like ultrasonography or CT scans, which can further limit the demand for MRI contrast agents.

Market Trends of the Gadoquatrane Market

The Gadoquatrane market is witnessing a significant shift towards safer imaging alternatives due to rising concerns over the side effects associated with gadolinium-based contrast agents, particularly in patients with renal impairments. As healthcare professionals and patients demand improved safety profiles, the focus is increasingly turning to gadolinium-free contrast agents, including innovative iron oxide nanoparticles and manganese-based compounds. This trend not only reflects a growing awareness of patient safety but also opens new avenues for research and development within the pharmaceutical industry. Consequently, the Gadoquatrane market is poised for growth as it aligns with these evolving patient care standards and technological advancements.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Gadoquatrane Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Diagnosis

Global Gadoquatrane Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital
• Diagnostic Centres
• Specialty Clinics
• Others

Global Gadoquatrane Market Size & CAGR (2025-2032)

• North America (Application, End User)
  • US
  • Canada
• Europe (Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spago Nanomedical AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trivitron Healthcare (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jodas Expoim Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CMR Naviscan Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Subhra Pharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrocyclics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• iMax Diagnostic Imaging Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Beilu Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanochemia Pharmazeutika AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations